Benedict Financial Advisors’s Gain Therapeutics GANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.4K Sell
13,500
-21,500
-61% -$39.2K ﹤0.01% 136
2026
Q2
$71K Buy
35,000
+19,500
+126% +$35.9K 0.01% 142
2026
Q1
$30.1K Sell
15,500
-22,500
-59% -$49K 0.01% 133
2025
Q4
$122K Buy
38,000
+3,000
+9% +$8.01K 0.03% 134
2025
Q3
$62K Buy
35,000
+12,500
+56% +$21.1K 0.01% 128
2025
Q2
$40.5K Buy
22,500
+4,500
+25% +$8.32K 0.01% 125
2025
Q1
$34.4K Buy
18,000
+2,000
+13% +$4.44K 0.01% 127
2024
Q4
$34.6K Buy
+16,000
New +$32.1K 0.01% 123

Other funds holding GANX

Benedict Financial Advisors's GANX Position: Q3 2026 in Review

Benedict Financial Advisors reduced its Gain Therapeutics (GANX) stake by 61% in Q3 2026, selling an estimated $39.2K and leaving 13,500 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #136.

Benedict Financial Advisors first reported a position in GANX in Q4 2024 and has held it in 8 quarters since. The position peaked at $122K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.

  • Benedict Financial Advisors held 13,500 shares of Gain Therapeutics worth $23.4K as of Q3 2026.
  • Benedict Financial Advisors sold 21,500 Gain Therapeutics shares in Q3 2026, an estimated $39.2K.
  • Gain Therapeutics made up ﹤0.01% of Benedict Financial Advisors's portfolio in Q3 2026, its #136 holding.
  • Benedict Financial Advisors first reported a position in Gain Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Benedict Financial Advisors's Gain Therapeutics position peaked at $122K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.

Based on Benedict Financial Advisors's 13F filing for Q3 2026, filed 7 Oct 2026.